ABSTRACT Synchronized coronary sinus retroperfusion (SCSR) 381-388, 1986. THE CONCEPT OF perfusing the heart via the coronary sinus is based on the observation that the coronary venous system is not affected by the atherosclerotic process . 1 It has been known since the late 1 800s5 that myocardial viability in animals can be maintained through retrograde flow of oxygenated blood via the coronary sinus. In the late 1940s, Beck and his colleagues6',7 demonstrated that shunting of arterialized blood to the coronary venous system could relieve angina in patients with chronic coronary artery disease. The major limitation of surgical retroperfusion was the inadequacy of venous drainage, which led to engorgement of the coronary sinus, myocardial edema, and heart failure. Beck's operation was superceded by direct myocardial revascularization with saphenous vein grafts, a more physiologically appealing
THE CONCEPT OF perfusing the heart via the coronary sinus is based on the observation that the coronary venous system is not affected by the atherosclerotic process . 1 It has been known since the late 1 800s5 that myocardial viability in animals can be maintained through retrograde flow of oxygenated blood via the coronary sinus. In the late 1940s, Beck and his colleagues6',7 demonstrated that shunting of arterialized blood to the coronary venous system could relieve angina in patients with chronic coronary artery disease. The major limitation of surgical retroperfusion was the inadequacy of venous drainage, which led to engorgement of the coronary sinus, myocardial edema, and heart failure. Beck's operation was superceded by direct myocardial revascularization with saphenous vein grafts, a more physiologically appealing procedure since it directly reestablishes antegrade blood flow to the myocardium.
A nonsurgical approach to coronary sinus retroperfusion was reported by Meerbaum et al.8 in 1976 . This system was synchronized to the cardiac cycle to deliver blood into the coronary sinus during diastole and allow normal physiologic drainage during systole. Several reports in dogs and baboons have confirmed the beneficial effects"'3 and safety of synchronized retroperfusion}.14' 11 In our own laboratory, we have studied the safety and efficacy of synchronized retroperfusion for up to 24 hr in dogs. '5 No significant change in blood pressure, pulse, cardiac output, or right-sided pressures were noted in the 38 animals studied. Myocardial damage, as documented by triphenyltetrazolium chloride staining, was limited to a small area in the subendocardial layer. Postmortem examination of animals revealed no histologic evidence of damage to the coronary sinus or surrounding structures. In addition, myocardial viability was maintained during left anterior descending coronary artery occlusion. Accordingly, we initiated an FDA-approved trial to evaluate the feasibility and safety of this intervention in humans in a clinical setting that might also allow a preliminary assessment of efficacy. We selected critically ill patients with unstable angina who were unresponsive to "maximal" medical therapy.
Methods
Instrumentation. A synchronous retroperfusion system (USCI Model ECI) was developed to deliver pulsatile arterialized blood to the coronary sinus during diastole with venous drainage occurring during systole (figure 1). The system consists of a physiologic monitor, a pump controller, a pistondriven pump, and an extracorporeal circuit. The monitor is a two-channel unit capable of monitoring and displaying the electrocardiogram and pressure or pump timing. Information from the monitor is fed to and processed by the pump controller, which maintains pump flow and pump timing through feedback circuits that compensate for variations in the patient's heart rhythm and rate. The extracorporeal blood circuit consists of a disposable piston-driven pump chamber assembly; tubing connects the arterial blood supply and SRP balloon catheters once they have been positioned in the patient.
Catheter system. Retroperfusate (arterial blood) is obtained through a No. 8F, 40 cm supply catheter (USCI) placed through a No. 8F catheter introducer (USCI Hemaquet) inserted into the femoral artery. A No. 7F, 56 cm autoinflatable retroperfusion balloon catheter (USCI) is positioned in the great cardiac vein 2 to 3 cm proximal to the anterior interventricular vein (figure 2) via the coronary sinus with use of a No. 9F catheter introducer (USCI) with a diaphragm-occluded sidearm is positioned in the internal jugular vein. As arterial blood is delivered through the coronary sinus catheter during diastole, it inflates a balloon at the tip of the catheter. This retards efflux from the regional coronary veins and permits more effective retrograde delivery of arterial blood to the myocardium. On termination of retrograde catheter perfusion at end-diastole, the occluding balloon automatically deflates (as documented by fluoroscopy and contrast injection), thereby allowing prograde coronary sinus drainage of venous blood from the myocardium into the right atrium during systole (figure 3).
Patient selection. Patients in the coronary care unit with unstable angina were eligible for this intervention if they had not responded to "maximum" medical therapy and were believed to be at extremely high risk for a fatal cardiac event. Unstable angina during bed rest was defined as multiple episodes of pain lasting more than 5 min but not longer than 30 min that were associated with electrocardiographic ST segment elevation or depression in two consecutive leads of at least 1.5 mm that normalized as the pain subsided and with creatinine kinase elevation less than two times the upper limits of normal. Patients with the following conditions were excluded: persistent arterial hypertension (systolic blood pressure >200 mm Hg) or hypotension (systolic blood pressure <90 mm Hg), significant valvular heart disease, coagulation defects or thrombocytopenia, any contraindication to heparinization, advanced cardiac conduction abnormalities, and/or inability to give informed consent. All patients had received maximal medical therapy for unstable angina in the coronary care unit, including oxygen, morphine, intravenous nitroglycerin, sublingual nitroglycerin, ,3-blockers, and calcium-channel blockers. position, introducers were placed percutaneously in the internal jugular vein and femoral artery. The arterial supply catheter was positioned in the distal aorta. The coronary sinus catheter was then advanced through the right atrium and into the coronary sinus under fluoroscopic guidance. Position in the coronary sinus was verified when a blood oxygen saturation of less than 40% was observed and was checked after the injection, by hand, of contrast material (Renografin 76, Squibb) (figure 4). The coronary sinus catheter was then advanced over a wire such that its tip was positioned in the great cardiac vein. Unimpeded emptying of the coronary sinus was verified by free flow of contrast material into the right atrium during systole. After arterial and venous cannulation each patient received 5000 units iv heparin in a bolus, followed by a constant heparin infusion to maintain the activated clotting time at 2 to 21/2 times control. During the period of synchronized coronary sinus retroperfusion, patients were maintained on the same cardiac medications and at the identical doses they had received over the 36 hr before intervention.
Pulmonary arterial flow-directed catheters were placed in four of the five patients. In all patients continuous arterial blood pressure was monitored through the sidearm of the femoral artery introducer. Retroperfusion was instituted at an arbitrarily predetermined flow rate of 0.5 ml/kg/min and increased every 10 min until relief of ischemic symptoms or a maximum flow rate of 2.2 ml/kg/min (or 150 ml/min, the maximum output of the system) had been achieved. The electrocardiogram was monitored continuously. All patients were maintained on synchronized coronary sinus retroperfusion until cardiac catheterization was performed. At that time a decision about definitive therapy, including the feasibility of coronary artery angioplasty or bypass surgery, was made. It was clearly understood that in some patients, because of the severity of their illness, no further mechanical intervention would be feasible.
Results

Feasibility
Coronary sinus retroperfusion. The procedure was successfully implemented in the five consecutive patients in which it was attempted. The patients ranged in age from 44 to 80 years; there were four men and one woman. All patients were critically ill and demonstrated significant ischemia of the anterior wall as docu- the coronary sinus catheter was 5 min, with a range of 30 sec to 10 min. Within 3 to 5 min after the catheters had been positioned, patients were placed on the pump by connecting the pump chamber inlet tubing to the arterial catheter, displacing the heparinized saline from the tubing with the patient's own oxygenated blood under arterial pressure, and connecting the outlet tubing to the coronary sinus catheter. Coronary sinus retroperfusion was arbitrarily instituted at 0.5 ml/kg/min in all patients. The mean coronary sinus ADuring the 36 hr just before synchronized coronary sinus retroperfusion.
BThere was no change in the amount or frequency of any oral antianginal medication during the 36 hr before and during retroperfusion.
fore retroperfusion to 0.0 tablets during the procedure (p < .05).
Subsequent clinical course. Coronary angiography was performed 1 to 18 hr after the institution of retroperfusion. Cardiac catheterization and angiography was performed during retroperfusion. As shown in table 1, all five patients had significant coronary artery disease with marked coronary stenoses in the distribution of the left anterior descending artery. Three of the five patients underwent emergency coronary artery bypass surgery. Two patients were not considered candidates for bypass surgery because of diffuse distal disease; these individuals were treated with an intra-aortic balloon pump, as per our protocol, after synchronized coronary sinus retroperfusion was discontinued. These latter two patients died 48 and 72 hr after intra-aortic balloon counterpulsation had been terminated. Of the patients undergoing coronary artery bypass grafting, two had an uncomplicated hospital course and were discharged 1 week after bypass surgery. The third patient had a prolonged postoperative course with respiratory and renal failure secondary to sepsis that occurred on the seventh postoperative day. None of these complications were believed to be related to the use of synchronized coronary sinus retroperfusion in these patients. Rather, they represented the natural history and progression of the underlying disease.
Discussion
In animals, synchronized coronary sinus retroperfusion has been validated as a relatively simple technique for the maintenance of myocardial viability in an infarct preparation of coronary occlusion. In that study, synchronized coronary sinus retroperfusion was instituted 30 min after the onset of ischemia, and then maintained for 6 hr. However, concern about the safety and the feasibility of the technique has delayed its clinical application. 8' 13 Our study demonstrates the feasibility and safety of synchronized coronary sinus retroperfusion in five patients with unstable angina resistant to maximal medical therapy. The procedure can be performed expeditiously at the bedside and maintained for at least 50 hr with no apparent adverse hemodynamic, hematologic, pathologic, or clinical effects.
Feasibility of synchronized coronary sinus retroperfusion. A major concern about synchronized coronary sinus retroperfusion is related to the ease with which the coronary sinus catheter can be placed. The design of this catheter allows for relatively easy placement from the internal jugular or subclavian vein. In all patients in this study, the catheter was placed directly into the coronary sinus with the use of fluoroscopy. In two of the five patients, a guidewire was required to advance the catheter further into the great cardiac vein. Satisfactory positioning of the catheter must be confirmed by measurement of the coronary sinus blood oxygen saturation or by a hand-powered contrast injection and visualization of the coronary sinus radiographically. Synchronized coronary sinus retroperfusion was safely implemented and utilized to control myocardial ischemia in two patients in whom significant peripheral vascular disease precluded intra-aortic balloon counterpulsation.
Safety of synchronized coronary sinus retroperfusion.
This system appears to be safe, since no untoward hemodynamic, hematologic, pathologic, or adverse clinical effects were noted in this small pilot series. There was a tendency for heart rate to decrease while blood pressure remained unchanged. Inspection of the heart at the time of coronary artery bypass surgery revealed ecchymosis on the anterior surface in one patient and a small hematoma in the area of the coronary sinus in another. These findings are in keeping with those of Drury et al. 14 in animals. Pressure in the regional coronary veins may be a potential cause of the anterior ecchymosis, and the coronary sinus catheter was probably the cause of the periadventitial hemorrhage around the coronary sinus. Our patients experienced no discomfort during synchronized coronary sinus retroperfusion. Muffling of the retroperfusion pumping mechanism may make it less disturbing to patients and staff as compared with intra-aortic balloon pumping. In two patients synchronized coronary sinus retroperfusion was maintained beyond 24 hr because it was well tolerated and effective in relieving myocardial ischemia.
The institution of synchronized coronary sinus retroperfusion to augment blood flow to areas of jeopardized myocardium did not cause any detectable hemodynamic alteration. All patients tolerated the augmentation of coronary sinus blood flow from 0.5 to 1.5 milkg/min with minimal adverse effects.
Preliminary assessment of efficacy. The intent of this initial trial of synchronized coronary sinus retroperfusion was to determine if it could be safely used in critically ill humans. Patients selected were those presenting with multiple episodes of acute anterior ischemia as evidenced by reversible precordial electrocardiographic changes. Based on experience in animals, it was believed that patients deriving maximal benefit from this intervention would be those with ischemia in the distribution of the left anterior descending coronary artery. In choosing patients with little or no elevation 386 CIRCULATION in total creatinine kinase, we hoped to select individuals with predominantly ischemic, and therefore potentially salvageable, myocardium. It must be emphasized that these five patients were not the usual unstable angina patients. Rather, they were all critically ill individuals whose disease was not controlled with maximal medical therapy and who required some further intervention for stabilization before catheterization, and synchronized coronary sinus retroperfusion was believed to be a reasonable alternative. Although the primary purpose of these initial studies was to assess feasibility and safety in a clinical setting, patients with unstable angina were selected to permit a preliminary assessment of efficacy. In four of five patients there was improvement with respect to the electrocardiographic manifestations of ischemia within 10 min. In the only patient in whom there was no electrocardiographic improvement, a total occlusion of the circumflex artery and a posterior wall infarction were present.
With each patient serving as his own control, there was significant improvement in each individual's clinical status during synchronized coronary sinus retroperfusion. Recognizing that unstable angina can vary on an hour-to-hour basis, clinical observations were made over a sufficiently long period (36 hr) before synchronized coronary sinus retroperfusion for comparison with similar variables observed during retroperfusion. Relief of symptoms within 10 min after the institution of retroperfusion therapy, recurrence of angina when the intervention was discontinued, and the attenuation of requirements for pain medication during retroperfusion suggest clinical benefit.
Technical limitations. Animal studies have verified that arterialized blood is required for retroperfusion to be effective since venous blood does not alleviate myocardial ischemia.'0 Thus, cannulation of an artery as well as the coronary sinus is required. Although fluoroscopy is presently required to place the coronary sinus catheter, further advances in design may decrease the fluoroscopy time required for placement of the catheter in the coronary sinus.
To date, the effects of synchronized coronary sinus retroperfusion have only been studied over a relatively short time period. The potential effects on formed blood elements and/or the heart itself of longer exposure to retroperfusion are unknown.
Future directions with synchronized coronary sinus retroperfusion. There are numerous potential applications for synchronized coronary sinus retroperfusion. Although this treatment was initially evaluated in patients with unstable angina, we are presently assessing the potential of this technique to alleviate myocardial ischemia during coronary artery angioplasty procedures.
Retrograde infusion of pharmacologic agents via the coronary sinus is another area of potential application; for example, cold cardioplegic solution could be infused by this method during open heart surgery."6 17 Preliminary animal studies at our institution'6 have shown that excellent myocardial cooling is achieved in dogs on cardiopulmonary bypass with continuous pulsatile coronary sinus cardioplegia.
Other potential clinical uses of synchronized coronary sinus retroperfusion that have been evaluated in animals but not yet in humans include instillation of thrombolytic agents, vasodilators, and antiarrhythmic drugs.'>2' Retrograde coronary sinus retroperfusion may also have an application in cardiac transplantation. Canine hearts have been preserved for 24 to 36 hr by retrograde perfusion through the coronary sinus, with functional recovery.22
